Total | bDMARD started < 2 years after disease onset | bDMARD started 2–5 years after disease onset | bDMARD started > 5 years after disease onset | p-value | |
---|---|---|---|---|---|
Disease activity (n assessed: 225) | |||||
Active (N/%) | 91 (40.4) | 5 (5.5) | 8 (8.8) | 78 (85.7)c | < 0.001* |
Remission on medication (N/%) | 79 (35.1)c | 10 (12.6) | 12 (15.1) | 57 (72.1) | 0.156 |
Remission off medication (N/%) | 54 (24)c | 8 (14.8)c | 14 (25.9) | 32 (59.2) | < 0.001* |
JADI-A (n assessed: 158; median (IQR)) | 1 (0–14.5) | 0 (0–1)a | 0 (0–1)b | 3 (0–28)a,b | 0.002* |
JADI-E (n assessed: 158; median (IQR)) | 0 (0–1) | 0 (0–0)a | 0 (0–0) | 0 (0–2)a | 0.013* |
HAQ (n assessed: 283; median (IQR)) | 0.25 (0–1) | 0 (0–0.25)c | 0 (0–0.09)b | 0.5 (0–1.25)a,b | < 0.001* |
SF36 physical component (n assessed: 218; median (IQR)) | 41.9 (29.9–53.2) | 56.2 (44.2–58.6)c | 49.5(44.0–57.8)b | 40.2 (32.9–64.4)a,b | 0.001 |
SF36 PF (median (IQR)) | 67.5 (40–95) | 97.5 (82.5–100) | 92.5 (70–100)b | 55 (30–90)a,b | < 0.001* |
SF36 RP (median (IQR)) | 93.8 (25–100) | 100 (64.1–100) | 100 (87.5–100)b | 75 (25–100)b | 0.013* |
SF36 BP (median (IQR)) | 62 (41–84) | 73 (38.8–88) | 82 (61.3–96)b | 52 (41–84)b | 0.019* |
SF36 GH (median (IQR)) | 47 (32.8–67) | 73,5 (50.8–87)c | 45 (37–67) | 47 (30–67)a | 0.046 |
SF36 mental component (n assessed: 217; median (IQR)) | 48.1 (37.3–65.8) | 54.0 (32.9–64.4) | 58.4 (43.4–72.1) | 47.4 (34.7–66.6) | 0.165 |
SF36 VT (median (IQR)) | 50 (40–75) | 65.6 (50–82.2) | 63.8 (55.3–79.7)b | 50 (40–69.4)b | 0.008* |
SF36 SF (median (IQR)) | 87.5 (51–100) | 87.5 (71.9–100) | 100 (78.1–100)b | 75 (50–100)b | 0.017* |
SF36 RE (median (IQR)) | 100 (64.6–100) | 100 (91.7–100) | 100 (100–100) | 100 (33.3–100) | 0.154 |
SF36 MH (median (IQR)) | 76 (60–88) | 86.5 (77.5–91.3) | 75 (61.4–90) | 76 (60–88) | 0.198 |
Joint surgery ever (n assessed: 361; N/%) | 61 (16.9) | 0 (0.0) | 1 (2.2) | 57 (24.1) | < 0.001* |